Integer Holdings Corporation Faces Securities Fraud Lawsuits
Analysis based on 35 articles · First reported Jan 28, 2026 · Last updated Feb 04, 2026
The market is negatively impacted by the alleged securities fraud by Integer Holdings Corporation, leading to a significant drop in its stock price. This event highlights the risks associated with investing in companies that may misrepresent their financial health and product demand, potentially increasing scrutiny on similar firms in the medical device industry.
Integer Holdings Corporation is facing multiple class action lawsuits for securities fraud. The lawsuits, filed by firms including Rosen Law Firm, Bleichmar Fonti & Auld LLP, and Kahn Swick & Foti, allege that Integer Holdings Corporation made materially false and misleading statements regarding its competitive position and demand for its electrophysiology (EP) devices between July 25, 2024, and October 22, 2025. The company allegedly overstated EP sales growth and market position while demand and revenue for these products had fallen sharply. On October 23, 2025, Integer Holdings Corporation disclosed lower 2025 sales guidance and projected poor net and organic sales growth for 2026, attributing it to slower-than-forecasted adoption of two EP devices. This announcement caused Integer Holdings Corporation's stock to plummet by over 32%, or $35.22 per share, from $109.11 to $73.89. Investors are being encouraged to join the class action lawsuits, which are pending in the United States===United States District Court for the Southern District of New York, with a lead plaintiff deadline of February 9, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard